These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 19663667)

  • 1. Discordant somatic and germline VEGF-A genotype in a cancer patient resistant to paclitaxel/bevacizumab with chemosensitive hepatic metastasis.
    Coltelli L; Allegrini G; Orlandi P; Giuntini N; Alì G; Fioravanti A; Bona E; Barletta MT; Fontanini G; Del Tacca M; Danesi R; Falcone A; Bocci G
    Pharmacogenomics; 2009 Aug; 10(8):1225-9. PubMed ID: 19663667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100.
    Schneider BP; Wang M; Radovich M; Sledge GW; Badve S; Thor A; Flockhart DA; Hancock B; Davidson N; Gralow J; Dickler M; Perez EA; Cobleigh M; Shenkier T; Edgerton S; Miller KD;
    J Clin Oncol; 2008 Oct; 26(28):4672-8. PubMed ID: 18824714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.
    Gianni L; Romieu GH; Lichinitser M; Serrano SV; Mansutti M; Pivot X; Mariani P; Andre F; Chan A; Lipatov O; Chan S; Wardley A; Greil R; Moore N; Prot S; Pallaud C; Semiglazov V
    J Clin Oncol; 2013 May; 31(14):1719-25. PubMed ID: 23569311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bevacizumab in the treatment of metastatic breast cancer: three case reports.
    Ferreira A; Vieira C; Rodrigues A; Pereira D; Rodrigues H; Dávila C; Bento S
    Curr Opin Oncol; 2011 Apr; 23 Suppl():S11-9. PubMed ID: 21490480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The potential of anti-vascular endothelial growth factor therapy in metastatic breast cancer: clinical experience with anti-angiogenic agents, focusing on bevacizumab.
    Marty M; Pivot X
    Eur J Cancer; 2008 May; 44(7):912-20. PubMed ID: 18396037
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Race to report: are vascular endothelial growth factor genetic polymorphisms associated with outcome in advanced breast cancer patients treated with Paclitaxel plus bevacizumab?
    Tan MH; Tan CS; Lim WY
    J Clin Oncol; 2009 Mar; 27(8):1342; author reply 1342-3. PubMed ID: 19188671
    [No Abstract]   [Full Text] [Related]  

  • 7. Association of VEGF-A splice variant mRNA expression with outcome in bevacizumab-treated patients with metastatic breast cancer.
    Pentheroudakis G; Kotoula V; Kouvatseas G; Charalambous E; Dionysopoulos D; Zagouri F; Koutras A; Papazisis K; Pectasides D; Samantas E; Dimopoulos MA; Papandreou CN; Fountzilas G
    Clin Breast Cancer; 2014 Oct; 14(5):330-8. PubMed ID: 24703319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Infusional fluorouracil, epirubicin, and cisplatin followed by weekly paclitaxel plus bevacizumab in locally advanced breast cancer with unfavorable prognostic features.
    Balduzzi A; Montagna E; Bagnardi V; Torrisi R; Bertolini F; Mancuso P; Scarano E; Viale G; Veronesi P; Cardillo A; Orlando L; Goldhirsch A; Colleoni M
    Anticancer Drugs; 2009 Mar; 20(3):197-203. PubMed ID: 19182679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bevacizumab: new indication. Metastatic breast cancer: many adverse effects.
    Prescrire Int; 2008 Dec; 17(98):236. PubMed ID: 19422148
    [No Abstract]   [Full Text] [Related]  

  • 10. Bevacizumab combined with two-weekly paclitaxel as first-line therapy for metastatic breast cancer.
    Kountourakis P; Doufexis D; Maliou S; Karagiannis A; Kardara E; Margari C; Sykoutri D; Tzovaras A; Ardavanis A
    Anticancer Res; 2010 Jul; 30(7):2969-71. PubMed ID: 20683040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Angiogenesis inhibition in the treatment of lung cancer.
    Vokes E; Herbst R; Sandler A
    Clin Adv Hematol Oncol; 2006 Nov; 4(11 Suppl 23):1-10; quiz 11-2. PubMed ID: 17143257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paclitaxel and bevacizumab as first line combined treatment in patients with metastatic breast cancer: the Hellenic Cooperative Oncology Group experience with biological marker evaluation.
    Fountzilas G; Kourea HP; Bobos M; Televantou D; Kotoula V; Papadimitriou C; Papazisis KT; Timotheadou E; Efstratiou I; Koutras A; Pentheroudakis G; Christodoulou C; Aravantinos G; Miliaras D; Petraki K; Papandreou CN; Papakostas P; Bafaloukos D; Repana D; Razis E; Pectasides D; Dimopoulos AM
    Anticancer Res; 2011 Sep; 31(9):3007-18. PubMed ID: 21868552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modified resistance to chemotherapy and trastuzumab by bevacizumab in locally recurrent breast cancer.
    Farhat MH; El-Saghir NS; Shamseddine AI
    Breast; 2009 Feb; 18(1):66-8. PubMed ID: 19013064
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bevacizumab for the first-line treatment of human epidermal growth factor receptor 2-negative advanced breast cancer.
    Damasceno M
    Curr Opin Oncol; 2011 Apr; 23 Suppl():S3-9. PubMed ID: 21490481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. VEGF as a marker for outcome among advanced breast cancer patients receiving anti-VEGF therapy with bevacizumab and vinorelbine chemotherapy.
    Burstein HJ; Chen YH; Parker LM; Savoie J; Younger J; Kuter I; Ryan PD; Garber JE; Chen H; Campos SM; Shulman LN; Harris LN; Gelman R; Winer EP
    Clin Cancer Res; 2008 Dec; 14(23):7871-7. PubMed ID: 19047116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bevacizumab and paclitaxel for breast cancer patients with central nervous system metastases: a case series.
    Labidi SI; Bachelot T; Ray-Coquard I; Mosbah K; Treilleux I; Fayette J; Favier B; Galy G; Blay JY; Guastalla JP
    Clin Breast Cancer; 2009 May; 9(2):118-21. PubMed ID: 19433393
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Usefulness of bevacizumab combination chemotherapy for advanced breast cancer].
    Aomatsu N; Kashiwagi S; Morisaki T; Ishihara S; Asano Y; Watanabe M; Noda S; Kawajiri H; Takashima T; Onoda N; Ishikawa T; Hirakawa K
    Gan To Kagaku Ryoho; 2013 Nov; 40(12):2393-5. PubMed ID: 24394123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Salvage treatment in metastatic breast cancer with weekly paclitaxel and bevacizumab.
    Polyzos A; Kalbakis K; Kentepozidis N; Giassas S; Kalykaki A; Vardakis N; Bozionelou V; Saloustros E; Kontopodis E; Georgoulias V; Mavroudis D
    Cancer Chemother Pharmacol; 2011 Jul; 68(1):217-23. PubMed ID: 20922389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bevacizumab for advanced breast cancer.
    Traina TA; Rugo HS; Dickler M
    Hematol Oncol Clin North Am; 2007 Apr; 21(2):303-19. PubMed ID: 17512451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of trastuzumab/docatexel combination on breast cancer angiogenesis: dichotomus effect predictable by the HIFI alpha/VEGF pre-treatment status?
    Koukourakis MI; Simopoulos C; Polychronidis A; Perente S; Botaitis S; Giatromanolaki A; Sivridis E
    Anticancer Res; 2003; 23(2C):1673-80. PubMed ID: 12820439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.